BRIUMVI Catalyst

The company’s 2025 earnings release underscored the centrality of BRIUMVI, noting the drug’s proven efficacy in reducing relapse and MRI activity in highly active relapsing multiple sclerosis. A clinical milestone for azercabtagene zapreleucel (azer‑cel) in progressive MS, which generated a $7.5 million payment from Precision BioSciences, marked the first substantive expansion beyond the BRIUMVI franchise. TG’s pipeline now includes two MS‑focused assets, but the subcutaneous BRIUMVI rollout remains the near‑term catalyst, as it could unlock a significant portion of the anti‑CD20 MS market.